Influenza Virus
6
1
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
COMMUNITY - the COVID-19 Immunity Study
Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
Tropism and Pathogenesis of Influenza Virus and Coronavirus in Human Brain Explant Culture
A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus
Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients
Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults